Pharmaceutical Industry: 100%
Top 3 Markets:

1. USA: approximately 60%
2. India: approximately 15%
3. Europe: approximately 10%

Gland Pharma Limited generates its revenues entirely from the pharmaceutical industry, with a focus on the manufacturing and distribution of injectable drugs. The US market is the largest revenue contributor, driven by strong demand for generic injectable medications. India and Europe follow as important markets, with India benefiting from local production and distribution, and Europe being strengthened by strategic partnerships and approvals.

Production Sites: Hyderabad, India

Gland Pharma Limited mainly produces its products in Hyderabad, India. The city is a significant hub for the pharmaceutical industry and offers a well-developed infrastructure as well as access to qualified personnel.

The company operates several production facilities in the region specializing in the manufacturing of injectable medicines. This strategic location choice enables Gland Pharma to produce efficiently and meet the high quality standards of international markets.

Revenue Growth: Estimated 10-12% annually (2026) Focus on International Markets: Expansion in the USA and Europe

Gland Pharma Limited pursues a growth strategy that is strongly focused on geographical expansion and diversification of the product portfolio. The company plans to further expand its presence in international markets, especially in the USA and Europe. These markets offer significant growth opportunities due to high demand for generic and specialized pharmaceutical products.

In addition, Gland Pharma is investing in research and development to develop innovative and cost-effective products. This includes both expanding existing product lines and introducing new products targeting specific therapeutic areas.

Another strategic focus is on optimizing production capacities and increasing efficiency in the supply chain to reduce costs and improve margins. Through these measures, the company aims to enhance its competitiveness and ensure long-term profitable growth.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials

Countries of origin: China, USA, Europe

Gland Pharma Limited mainly imports active pharmaceutical ingredients (APIs) that are crucial for the production of their products. A significant portion of these APIs is sourced from China, as the country is one of the largest producers of pharmaceutical raw materials worldwide.

In addition, the company imports excipients and packaging materials from various countries, including the USA and European countries. These materials are necessary to meet the quality standards and regulatory requirements for exporting to international markets.

Market Share: 5% in the Indian pharmaceutical market (2025, estimated)
R&D Expenses: 7% of revenue (2025)
EBITDA Margin: 30% (2025)

Gland Pharma Limited has a solid competitive advantage in the Indian pharmaceutical market, particularly due to its specialization in injectable medicines. The company benefits from strong production capacity and an efficient supply chain, allowing it to produce cost-effectively while maintaining high quality standards.

The continuous investments in research and development, accounting for about 7% of revenue, enhance the company's innovation capabilities and enable the introduction of new products. This helps to strengthen its market position and differentiate itself from competitors.

Furthermore, Gland Pharma boasts an impressive EBITDA margin of 30%, indicating an efficient cost structure and strong pricing. Together, these factors give the company a sustainable competitive edge in the global market for injectable medicines.

Institutional Investor Share: 45% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2026)

The institutional investor share in Gland Pharma Limited is estimated to be 45%. This demonstrates the confidence of institutional investors in the company and its future growth prospects.

In 2026, there were no significant insider buys or sells, indicating that the management and insiders are currently not making any significant changes in their assessment of the company. This could suggest a stable internal outlook on the company's development.

Market share of Gland Pharma Limited: Estimated 4% (2026)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 10%
2. Dr. Reddy's Laboratories: 8%
3. Cipla Ltd.: 7%
4. Aurobindo Pharma Ltd.: 6%
5. Lupin Ltd.: 5%
6. Gland Pharma Limited: 4%
7. Biocon Ltd.: 3%
8. Torrent Pharmaceuticals: 3%
9. Cadila Healthcare: 2%
10. Glenmark Pharmaceuticals: 2%

Gland Pharma Limited has a moderate market share in the Indian pharmaceutical market, which is dominated by large, established companies. Gland Pharma's moat lies in its specialization in injectable medicines and its strong presence in international markets, especially in the USA and Europe. This specialization allows the company to differentiate itself from generic drug manufacturers.

In comparison to larger competitors like Sun Pharmaceutical and Dr. Reddy's Laboratories, which have a broader product portfolio and extensive R&D resources, Gland Pharma's moat is less pronounced. These companies have a stronger competitive advantage due to their size and diversification.

In summary, Gland Pharma has a certain competitive advantage through its niche focus, but this advantage is limited compared to industry leaders. The larger competitors have more extensive resources and a broader market presence, giving them a stronger moat.

Revenue Growth: 10% (2025) Profit Growth: 8% (2025) Research and Development Expenses: 15% of Revenue (2025)

Gland Pharma Limited recorded solid revenue growth of 10% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. Profit growth stands at 8%, indicating efficient cost control and operational efficiency.

The company is investing 15% of its revenue in research and development, signaling a strategic focus on innovation and product development. This could lead to a stronger market position and new revenue streams in the long term.

Overall, Gland Pharma Limited demonstrates positive financial performance and strategic investment in future growth potential. This could make the stock an attractive investment, especially for investors interested in long-term growth opportunities.

Dividend yield: 1.5% (estimated for 2026)

Dividend history: Regular payouts in recent years

Gland Pharma Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2026 is around 1.5%, which is moderate compared to other companies in the industry.

The company has a solid financial foundation that allows it to maintain dividend payments. Analysts view Gland Pharma's dividend policy as stable, but investors should continue to monitor the financial performance and market conditions to assess the sustainability of the payouts.